- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05443126
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
April 18, 2024 updated by: Ellipses Pharma
A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies
Study Overview
Detailed Description
EP0031 is being investigated in this modular, interventional Phase I/II dose escalation and dose expansion study to investigate the optimal dose in adult patients with advanced RET-altered malignancies.
Currently there are no approved RET-targeted treatments for patients who progress on first-generation SRIs.
However, it is proposed that EP0031 can overcome resistance mechanisms to first generation SRIs, as EP0031 is a potent and selective RET inhibitor with broad activity against common RET fusions and mutations.
Study Type
Interventional
Enrollment (Estimated)
265
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Liz Clark
- Phone Number: +44 (0)20 3743 0992
- Email: Liz@ellipses.life
Study Contact Backup
- Name: Sonia Serrano
- Phone Number: +44 (0)20 3743 0992
- Email: sonia@ellipses.life
Study Locations
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitario Vall d'Hebron
-
Contact:
- Elena Garralda
- Email: egarralda@vhio.net
-
Madrid, Spain, 28034
- Recruiting
- Hospital Universitario Ramón y Cajal
-
Contact:
- Pilar Garrido Lopez
- Email: pgarrido@salud.madrid.org
-
Madrid, Spain, 28050
- Recruiting
- Hospital Madrid Sanchinarro
-
Contact:
- Irene Moreno
- Email: irene.moreno@startmadrid.com
-
Madrid, Spain, 28041
- Recruiting
- University Hospital October 12
-
Contact:
- Luis Paz-Ares
- Email: lpazares@ext.cnio.es
-
Málaga, Spain, 29010
- Recruiting
- Hospital Virgen de la Victoria de Malaga
-
Contact:
- Garcia Corbacho
- Email: jgcorbacho@ibima.eu
-
-
-
-
-
London, United Kingdom, NW1 2BU
- Recruiting
- University College London Hospital
-
Contact:
- Martin Forster
- Email: martin.forster1@nhs.net
-
London, United Kingdom, SE1 9RT
- Recruiting
- Guy's Hospital
-
Contact:
- Debashi Starker
- Email: debashis.sarker@kcl.ac.uk
-
Manchester, United Kingdom, M20 4BX
- Recruiting
- The Christie NHS Foundation Trust - Christie Hospital
-
Contact:
- Matthew Krebs
- Email: matthew.krebs@nhs.net
-
Sheffield, United Kingdom, S10 2JF
- Recruiting
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Contact:
- Jonathan Wadsley
- Email: jonathan.wadsley1@nhs.net
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- David Geffen School of Medicine at UCLA
-
Contact:
- Andrew Gianoukakis
- Email: agianoukakis@lundquist.org
-
Stanford, California, United States, 94305
- Recruiting
- Stanford University
-
Contact:
- Saad Khan
- Email: saad.a.khan@stanford.edu
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20057
- Recruiting
- Georgetown University
-
Contact:
- Stephen Liu
- Email: Stephen.Liu@gunet.georgetown.edu
-
-
Florida
-
Fort Myers, Florida, United States, 33908
- Recruiting
- Florida Cancer Specialist
-
Contact:
- Judy Wang
- Email: jswang@flcancer.com
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- Rush University Medical Center
-
Contact:
- Michael Jelinek
- Email: Michael_Jelinek@rush.edu
-
Evanston, Illinois, United States, 60208
- Recruiting
- Northwestern University
-
Contact:
- Jyoti Patel
- Email: jd-patel@northwestern.edu
-
-
Kentucky
-
Lexington, Kentucky, United States, 40506
- Recruiting
- University of Kentucky
-
Contact:
- Susanne Arnold
- Email: susanne.arnold@uky.edu
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Recruiting
- Karmanos
-
Contact:
- Ammar Sukari
- Email: schiavij@karmanos.org
-
-
New York
-
New York, New York, United States, 10016
- Recruiting
- NYU Langone Health
-
Contact:
- Salman Punekar
- Email: salman.punekar@nyulangone.org
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Recruiting
- Providence Portland Medical Centre
-
Contact:
- Matthew H Taylor
- Email: matthew.taylor@providence.org
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Sarah Cannon
-
Contact:
- David Spiegel
- Email: david.spigel@sarahcannon.com
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Contact:
- Sarina Piha-Paul
- Email: spihapau@mdanderson.org
-
-
Washington
-
Seattle, Washington, United States, 63130
- Recruiting
- Washington University
-
Contact:
- Daniel Morgensztern
- Email: danielmorgensztern@wustl.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Applicable to all patients:
- Must be ≥18 years of age at the time of informed consent, with documented RET-altered malignancy
- Patients should be well informed and consented about alternative treatment options including approved RET-targeted therapies
- ECOG performance status of 0 or 1 at screening
- Ability to understand and provide written informed consent and able to participate in all required evaluations and procedures
Exclusion Criteria:
Patients with any of the following will not be included in the study:
- Any known major driver gene alterations other than RET.
- Spinal cord compression or brain metastases. Patients with stable brain metastases can be enrolled.
- Active infection requiring systemic antibiotic, antifungal, or antiviral medication
- Severe or uncontrolled medical condition or psychiatric condition
- Chronic glomerulonephritis or renal transplant
- Patients with active hepatitis B infection or active hepatitis C
- Patients with active HIV infection. Patients living with HIV may be eligible if they have adequate CD4+ T-cell count and no history of AIDS-defining opportunistic infections in the past 12 months
- Receipt of any strong inhibitor or inducer of CYP3A4
- Impaired hepatic or renal function, inadequate bone marrow reserve or organ function
- Any clinically important abnormalities in rhythm, conduction, or morphology on resting ECG or any factor that increases the risk of QTc prolongation or of arrhythmic events , or congestive heart failure Grade II-IV according to the New York Heart Association, myocardial infarction, or unstable angina within the previous 6 months
- Uncontrolled hypertension
- Corneal ulceration at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RET fusion-positive NSCLC
EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
|
EP0031 is a potent next-generation selective RET-inhibitor (SRI)
|
Experimental: RET mutation-positive MTC
EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
|
EP0031 is a potent next-generation selective RET-inhibitor (SRI)
|
Experimental: Other RET-altered solid tumours
EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
|
EP0031 is a potent next-generation selective RET-inhibitor (SRI)
|
Experimental: RET fusion-positive NSCLC (no prior SRI therapy)
EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
|
EP0031 is a potent next-generation selective RET-inhibitor (SRI)
|
Experimental: RET mutation-positive MTC (no prior SRI therapy)
EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
|
EP0031 is a potent next-generation selective RET-inhibitor (SRI)
|
Experimental: Other RET-altered solid tumours (no prior SRI therapy)
EP0031 capsules at the recommended phII dose, taken once daily until progressive disease (PD), unacceptable toxicity or patient withdrawal
|
EP0031 is a potent next-generation selective RET-inhibitor (SRI)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Module A: Incidence of Dose-limiting Toxicity (DLTs ) during the first 28 days of EP0031 treatment
Time Frame: First 28 days of treatment
|
First 28 days of treatment
|
Modules B and C: Overall Response Rate (ORR) as measured using RECIST v1.1
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration versus time curve (AUC)
Time Frame: First 48 hours after drug administered
|
To characterise the pharmacokinetics (PK) of EP0031
|
First 48 hours after drug administered
|
Maximum Plasma Concentration (Cmax)
Time Frame: First 24 hours after drug administered
|
To characterise the pharmacokinetics (PK) of EP0031
|
First 24 hours after drug administered
|
Time taken for drug concentration to fall from half its original value (Half-life)
Time Frame: First 72 hours after drug administered
|
To characterise the pharmacokinetics (PK) of EP0031
|
First 72 hours after drug administered
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 30, 2022
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
June 1, 2027
Study Registration Dates
First Submitted
June 24, 2022
First Submitted That Met QC Criteria
July 1, 2022
First Posted (Actual)
July 5, 2022
Study Record Updates
Last Update Posted (Actual)
April 19, 2024
Last Update Submitted That Met QC Criteria
April 18, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EP0031-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor